[go: up one dir, main page]

WO2005034879A3 - Treatment of diseases involving erbb2 kinase overexpression - Google Patents

Treatment of diseases involving erbb2 kinase overexpression Download PDF

Info

Publication number
WO2005034879A3
WO2005034879A3 PCT/US2004/033355 US2004033355W WO2005034879A3 WO 2005034879 A3 WO2005034879 A3 WO 2005034879A3 US 2004033355 W US2004033355 W US 2004033355W WO 2005034879 A3 WO2005034879 A3 WO 2005034879A3
Authority
WO
WIPO (PCT)
Prior art keywords
erbb2 kinase
treatment
kinase overexpression
diseases involving
overexpression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/033355
Other languages
French (fr)
Other versions
WO2005034879A2 (en
Inventor
Harold H Schmitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mars Inc
Original Assignee
Mars Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mars Inc filed Critical Mars Inc
Priority to EP04809906A priority Critical patent/EP1670455A4/en
Priority to JP2006534418A priority patent/JP2007508316A/en
Priority to CA002541548A priority patent/CA2541548A1/en
Priority to AU2004280257A priority patent/AU2004280257A1/en
Publication of WO2005034879A2 publication Critical patent/WO2005034879A2/en
Publication of WO2005034879A3 publication Critical patent/WO2005034879A3/en
Priority to IL174763A priority patent/IL174763A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)

Abstract

The invention relates to compositions containing polyphenols such as flavanols and their related oligomers, and methods for treating conditions associated with ErbB2 kinase overexpression, for example, treatment of cancers involving ErbB2 kinase overexpression. Fig. 2 represents results from the real time PCR experiments verifying reduced expression of ErbB2 kinase in HAEC in the presence of procyanidins.
PCT/US2004/033355 2003-10-10 2004-10-08 Treatment of diseases involving erbb2 kinase overexpression Ceased WO2005034879A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP04809906A EP1670455A4 (en) 2003-10-10 2004-10-08 Treatment of diseases involving erbb2 kinase overexpression
JP2006534418A JP2007508316A (en) 2003-10-10 2004-10-08 Treatment of diseases associated with ErbB2 kinase overexpression
CA002541548A CA2541548A1 (en) 2003-10-10 2004-10-08 Treatment of diseases involving erbb2 kinase overexpression
AU2004280257A AU2004280257A1 (en) 2003-10-10 2004-10-08 Treatment of diseases involving ErbB2 kinase overexpression
IL174763A IL174763A0 (en) 2003-10-10 2006-04-03 TREATMENT OF DISEASES INVOLVING ErbB2 KINASE OVEREXPRESSION

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51060403P 2003-10-10 2003-10-10
US60/510,604 2003-10-10

Publications (2)

Publication Number Publication Date
WO2005034879A2 WO2005034879A2 (en) 2005-04-21
WO2005034879A3 true WO2005034879A3 (en) 2005-12-29

Family

ID=34435110

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/033355 Ceased WO2005034879A2 (en) 2003-10-10 2004-10-08 Treatment of diseases involving erbb2 kinase overexpression

Country Status (9)

Country Link
US (1) US20050245601A1 (en)
EP (1) EP1670455A4 (en)
JP (1) JP2007508316A (en)
CN (1) CN1889944A (en)
AU (1) AU2004280257A1 (en)
CA (1) CA2541548A1 (en)
IL (1) IL174763A0 (en)
RU (1) RU2006115615A (en)
WO (1) WO2005034879A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007002854A2 (en) * 2005-06-29 2007-01-04 Mars, Incorporated Inducing peripheral blood vessel vasodilation
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP1942879A1 (en) 2005-10-31 2008-07-16 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
EP2004208B1 (en) * 2005-12-23 2017-01-25 Mars, Incorporated Skin protection and improvement
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
JP2009536669A (en) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド Neurogenesis by angiotensin regulation
KR20090064418A (en) * 2006-09-08 2009-06-18 브레인셀즈 인코퍼레이션 Combination with 4-acylaminopyridine derivatives
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
AU2008265928A1 (en) * 2007-06-18 2008-12-24 Medimmune, Llc Synergistic treatment of cells that express EphA2 and ErbB2
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6420572B1 (en) * 1997-10-09 2002-07-16 Mars, Incorporated Synthetic methods for preparation of protected proanthocyanidin(s)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554645A (en) * 1994-10-03 1996-09-10 Mars, Incorporated Antineoplastic cocoa extracts and methods for making and using the same
US6297273B1 (en) * 1996-04-02 2001-10-02 Mars, Inc. Use of cocoa solids having high cocoa polyphenol content in tabletting compositions and capsule filling compositions
EP1015006A4 (en) * 1996-04-02 2003-09-24 Mars Inc Cocoa extract compounds and methods for making and using the same
US6156912A (en) * 1999-04-09 2000-12-05 Mars, Incorporated 88, 66, and 68 catechin and epicatechin dimers and methods for their preparation
US7015338B1 (en) * 1999-04-15 2006-03-21 Mars Incorporated Synthetic methods for preparing procyanidin oligomers

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6420572B1 (en) * 1997-10-09 2002-07-16 Mars, Incorporated Synthetic methods for preparation of protected proanthocyanidin(s)

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CANCER LETTERS., vol. 185, no. 2, 2002, pages 123 - 130 *
DATABASE CAPLUS [online] ITO H ET AL: "Antitumor activity of compounds isolated from leaves of Eriobotrya japonica.", XP002994313, Database accession no. (136:334883) *
DATABASE CAPLUS [online] YAMAGISHI M ET AL: "Effects of cacao liquor proanthocyanidins on PhIP-induced mutagenesis in vitro, and in vivo mammary and pancreatic tumorigenesis in female Sprague-Dawley rats.", XP002994314, Database accession no. (138:180310) *
J AGR & FOOD CHEM., vol. 50, no. 8, 2002, pages 2400 - 2403 *

Also Published As

Publication number Publication date
US20050245601A1 (en) 2005-11-03
CN1889944A (en) 2007-01-03
CA2541548A1 (en) 2005-04-21
WO2005034879A2 (en) 2005-04-21
AU2004280257A1 (en) 2005-04-21
EP1670455A4 (en) 2008-10-15
EP1670455A2 (en) 2006-06-21
IL174763A0 (en) 2008-04-13
RU2006115615A (en) 2007-11-27
JP2007508316A (en) 2007-04-05

Similar Documents

Publication Publication Date Title
WO2006024018A3 (en) Compositions for treating nociceptive pain
WO2007092622A3 (en) Compositions and methods for treating bone
WO2006135915A3 (en) Methods and compositions for treating degenerative bone disorders
WO2007064872A3 (en) Urea compounds useful in the treatment of cancer
WO2007053573A3 (en) Treatment of cancer with sorafenib
WO2006042249A3 (en) Methods and compositions for treating migraine pain
WO2005048948A3 (en) Urea derivatives as kinase modulators
WO2006073457A3 (en) Bioactive compounds and methods of uses thereof
WO2004080391A3 (en) Novel antibacterial agents
WO2005034879A3 (en) Treatment of diseases involving erbb2 kinase overexpression
WO2006083971A3 (en) Dr5 antibodies and uses thereof
WO2009118662A3 (en) Methods and compositions for treating bone loss
PL1664413T3 (en) Treated textiles and compositions for treating textiles
WO2004009062A3 (en) NMDA RECEPTOR ANTAGONISTS AND THEIR USE IN INHIBITING ABNORMAL HYPERPHOSPHORYLATION OF MICROTUBULE ASSOCIATED PROTEIN tau
IL142900A0 (en) Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
WO2007059202A3 (en) Pyrazolyl urea derivatives useful in the treatment of cancer
WO2007146335A3 (en) Compounds and compositions for treatment of cancer
WO2009009034A3 (en) Methods and compositions useful in the treatment of mucositis
WO2007109799A3 (en) Polymorphs of eszopiclone malate
WO2006113483A3 (en) Methods and compositions for treating or preventing cancer
WO2001087287A3 (en) Use of pyrazole derivatives for treating infertility
WO2007098047A3 (en) Methods and compositions for the treatment of parkinson's disease
WO2005007123A3 (en) Pin1-modulating compounds and methods of use thereof
WO2004091436A3 (en) Methods and compositions for treating ocular disease
WO2009033183A3 (en) Compounds and methods for treatment of hcv and conditions associated with cd81 binding

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480036220.4

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004809906

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 174763

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2541548

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004280257

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006534418

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2004280257

Country of ref document: AU

Date of ref document: 20041008

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004280257

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006115615

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2004809906

Country of ref document: EP